Get in touch
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact usDiscover how Myriad Associates played a pivotal role in securing grants for VERSONO Medical, revolutionising vascular healthcare. Explore our partnership and its impact.
In the world of medical innovation, breakthroughs can be life-changing, and the journey to achieving them often involves collaboration and expertise from multiple corners.
Today, we are excited to share a remarkable success story – one that highlights the power of partnership, dedication, and the pursuit of excellence.
Located in Galway, Ireland, VERSONO Medical is a pioneering medical innovation company dedicated to revolutionising the treatment of complex vascular diseases. Recently, VERSONO Medical achieved a significant milestone by securing not one but two prestigious grants. These grants will play a pivotal role in advancing their mission to transform healthcare for patients suffering from Critical Limb Threatening Ischemia (CLTI), the most severe form of peripheral vascular disease (PAD).
The first grant, awarded by the European Innovation Council, is set to support the finalisation and commercialisation of VERSONO Medical's groundbreaking FastWire technology. The second grant, provided by the Department of Enterprise Trade and Employment and Enterprise Ireland's Disruptive Technology Innovation Fund, will further contribute to the development of the company's product portfolio.
The importance of VERSONO Medical's work cannot be overstated. Peripheral Artery Disease (PAD) is on the rise globally, affecting millions of individuals worldwide. As individuals age, the prevalence of PAD increases exponentially, with more than 18% of those aged 70-75 being afflicted with the disease. CLTI, which mainly impacts the lower extremities, can lead to arterial blockages that restrict blood flow to limbs, raising the risk of necrosis, sepsis, amputation, and even death.
Current endovascular treatments can re-establish blood flow to affected areas, but the complexity of calcified arterial blockages in CLTI patients often poses technical challenges. Traditional treatments have not consistently crossed these barriers, increasing the probability of limb amputations.
Enter Myriad Associates, our exceptional grants team specialise in grant applications and securing funding for innovative projects. Our partnership with VERSONO Medical played a critical role in helping them secure these grants, making this achievement a testament to our commitment to fostering innovation and excellence in the Irish healthcare sector.
We worked closely with VERSONO Medical to prepare their grant applications, leveraging our expertise to maximise their chances of success. The result? A significant funding boost that will enable VERSONO Medical to accelerate their groundbreaking work in vascular healthcare.
VERSONO Medical's journey is one worth celebrating. The grants they've secured represent not only their dedication but also the potential to transform the lives of countless individuals affected by CLTI. The ability to prevent amputations and improve the prognosis for patients with vascular diseases is a monumental achievement.
As we look ahead, VERSONO Medical is preparing for a pivotal study of the FastWire device in the USA in 2024, marking another significant step towards bringing this innovative solution to market.
We are immensely proud of our partnership with VERSONO Medical and look forward to continuing to support their mission to revolutionise vascular disease treatment worldwide.
In conclusion, this success story reaffirms that collaboration, dedication, and expertise can lead to groundbreaking innovations that have the potential to change lives. We congratulate VERSONO Medical on this remarkable achievement and remain committed to supporting innovative endeavors that shape the future of healthcare.
A wealth of information is available on the Enterprise.gov website: https://enterprise.gov.ie/en/what-we-do/innovation-research-development/disruptive-technologies-innovation-fund/ .You are also of course welcome to discuss any aspect of innovation grant funding and how your business can benefit by contacting our team.
Our market-leading team is ready to put your company front and centre, aiming to secure the R&D grants in Ireland that elevates your innovation strategy to the next level.
Millions of euros on non-repayable grant funding could be at stake. Why not see what we can do for you. Contact us on +353 1 566 2001 or send us a message and we'll call you back.
DTIF Call 7 launched on 7 May 2024 as a ‘rolling’ call and will close at 5 pm on 30 April 2025.
Starting a successful business is scary - but you’re not alone. To help you financially along the way, there’s a massive range of grants, loans, tax breaks and other funding available.
Explore Taighde Éireann - Research Ireland, Ireland's new unified funding agency for research and innovation.
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact us